Metabolic changes due to iatrogenic hypogonadism in patients with prostate cancer: orchiectomy vs. triptorelin [Metaboliske ændringer hos patienter med prostatakræft som følge af iatrogen hypogonadisme: orkiektomi vs. triptorelin]

Trial Profile

Metabolic changes due to iatrogenic hypogonadism in patients with prostate cancer: orchiectomy vs. triptorelin [Metaboliske ændringer hos patienter med prostatakræft som følge af iatrogen hypogonadisme: orkiektomi vs. triptorelin]

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2016

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
    • 04 Apr 2016 Results comparing androgen status (n = 55) presented at The 98th Annual Meeting of the Endocrine Society.
    • 02 Apr 2016 Status changed from recruiting to completed, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top